Skip to main content
NCBI home page
Heart logoLink to Heart
. 1996 May;75(5):442–446. doi: 10.1136/hrt.75.5.442

Incidence of hibernating myocardium after acute myocardial infarction treated with thrombolysis.

J N Adams 1, M Norton 1, R J Trent 1, P Mikecz 1, S Walton 1, N Evans 1
PMCID: PMC484337  PMID: 8665333

Abstract

OBJECTIVE: To establish the incidence of hibernating myocardium after myocardial infarction treated with thrombolysis and to observe differences in the clinical outcome between patients with and without hibernating tissue. METHODS: 41 patients underwent gated positron emission tomography with 18-fluorodeoxyglucose and 13N-ammonia at a median of eight days after first myocardial infarction. RESULTS: All 41 subjects had a matched perfusion-metabolism deficit in the region of myocardium indicated as the site of infarction by an electrocardiograph; 32 patients (78%) had scans which also showed at least one area of reduced blood flow and contraction with a concomitant increase in glucose uptake, representing hibernating myocardium. Patients were followed up at a median of six months: all 41 were alive and none had sustained a further infarct or cardiac arrhythmia; 17 subjects with hibernating tissue (53.1%) and two without (25%) reported chest pain after myocardial infarction. CONCLUSIONS: Hibernating myocardium is relatively common shortly after myocardial infarction treated with thrombolysis. It does not influence mortality or the incidence of postinfarction chest pain.

Full text

PDF
442

Images in this article

443Image
on p.443
446Image
on p.446
446Image
on p.446

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergmann S. R., Hack S., Tewson T., Welch M. J., Sobel B. E. The dependence of accumulation of 13NH3 by myocardium on metabolic factors and its implications for quantitative assessment of perfusion. Circulation. 1980 Jan;61(1):34–43. doi: 10.1161/01.cir.61.1.34. [DOI] [PubMed] [Google Scholar]
  2. Bonow R. O., Dilsizian V., Cuocolo A., Bacharach S. L. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation. 1991 Jan;83(1):26–37. doi: 10.1161/01.cir.83.1.26. [DOI] [PubMed] [Google Scholar]
  3. Braunwald E., Rutherford J. D. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol. 1986 Dec;8(6):1467–1470. doi: 10.1016/s0735-1097(86)80325-4. [DOI] [PubMed] [Google Scholar]
  4. Brunken R. C., Kottou S., Nienaber C. A., Schwaiger M., Ratib O. M., Phelps M. E., Schelbert H. R. PET detection of viable tissue in myocardial segments with persistent defects at T1-201 SPECT. Radiology. 1989 Jul;172(1):65–73. doi: 10.1148/radiology.172.1.2787037. [DOI] [PubMed] [Google Scholar]
  5. Brunken R., Schwaiger M., Grover-McKay M., Phelps M. E., Tillisch J., Schelbert H. R. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol. 1987 Sep;10(3):557–567. doi: 10.1016/s0735-1097(87)80198-5. [DOI] [PubMed] [Google Scholar]
  6. Collen D., Topol E. J., Tiefenbrunn A. J., Gold H. K., Weisfeldt M. L., Sobel B. E., Leinbach R. C., Brinker J. A., Ludbrook P. A., Yasuda I. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984 Dec;70(6):1012–1017. doi: 10.1161/01.cir.70.6.1012. [DOI] [PubMed] [Google Scholar]
  7. Czernin J., Porenta G., Brunken R., Krivokapich J., Chen K., Bennett R., Hage A., Fung C., Tillisch J., Phelps M. E. Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction. Circulation. 1993 Sep;88(3):884–895. doi: 10.1161/01.cir.88.3.884. [DOI] [PubMed] [Google Scholar]
  8. Dilsizian V., Rocco T. P., Freedman N. M., Leon M. B., Bonow R. O. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med. 1990 Jul 19;323(3):141–146. doi: 10.1056/NEJM199007193230301. [DOI] [PubMed] [Google Scholar]
  9. Downing S. E., Chen V. Acute hibernation and reperfusion of the ischemic heart. Circulation. 1992 Feb;85(2):699–707. doi: 10.1161/01.cir.85.2.699. [DOI] [PubMed] [Google Scholar]
  10. Eitzman D., al-Aouar Z., Kanter H. L., vom Dahl J., Kirsh M., Deeb G. M., Schwaiger M. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol. 1992 Sep;20(3):559–565. doi: 10.1016/0735-1097(92)90008-b. [DOI] [PubMed] [Google Scholar]
  11. Goris M. L., Thompson C., Malone L. J., Franken P. R. Modelling the integration of myocardial regional perfusion and function. Nucl Med Commun. 1994 Jan;15(1):9–20. doi: 10.1097/00006231-199401000-00003. [DOI] [PubMed] [Google Scholar]
  12. Lange K., Carson R. EM reconstruction algorithms for emission and transmission tomography. J Comput Assist Tomogr. 1984 Apr;8(2):306–316. [PubMed] [Google Scholar]
  13. Liu P., Kiess M. C., Okada R. D., Block P. C., Strauss H. W., Pohost G. M., Boucher C. A. The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischemia? Am Heart J. 1985 Nov;110(5):996–1001. doi: 10.1016/0002-8703(85)90199-1. [DOI] [PubMed] [Google Scholar]
  14. Marshall R. C., Tillisch J. H., Phelps M. E., Huang S. C., Carson R., Henze E., Schelbert H. R. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography, 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation. 1983 Apr;67(4):766–778. doi: 10.1161/01.cir.67.4.766. [DOI] [PubMed] [Google Scholar]
  15. Marwick T. H., Nemec J. J., Lafont A., Salcedo E. E., MacIntyre W. J. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol. 1992 Apr 1;69(9):854–859. doi: 10.1016/0002-9149(92)90782-t. [DOI] [PubMed] [Google Scholar]
  16. Piérard L. A., De Landsheere C. M., Berthe C., Rigo P., Kulbertus H. E. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol. 1990 Apr;15(5):1021–1031. doi: 10.1016/0735-1097(90)90236-i. [DOI] [PubMed] [Google Scholar]
  17. Schelbert H. R., Phelps M. E., Hoffman E. J., Huang S. C., Selin C. E., Kuhl D. E. Regional myocardial perfusion assessed with N-13 labeled ammonia and positron emission computerized axial tomography. Am J Cardiol. 1979 Feb;43(2):209–218. doi: 10.1016/s0002-9149(79)80006-5. [DOI] [PubMed] [Google Scholar]
  18. Schelbert H. R., Phelps M. E., Huang S. C., MacDonald N. S., Hansen H., Selin C., Kuhl D. E. N-13 ammonia as an indicator of myocardial blood flow. Circulation. 1981 Jun;63(6):1259–1272. doi: 10.1161/01.cir.63.6.1259. [DOI] [PubMed] [Google Scholar]
  19. Schoeder H., Friedrich M., Topp H. Myocardial viability: what do we need? Eur J Nucl Med. 1993 Sep;20(9):792–803. doi: 10.1007/BF00180911. [DOI] [PubMed] [Google Scholar]
  20. Schwaiger M., Brunken R. C., Krivokapich J., Child J. S., Tillisch J. H., Phelps M. E., Schelbert H. R. Beneficial effect of residual anterograde flow on tissue viability as assessed by positron emission tomography in patients with myocardial infarction. Eur Heart J. 1987 Sep;8(9):981–988. doi: 10.1093/oxfordjournals.eurheartj.a062375. [DOI] [PubMed] [Google Scholar]
  21. Schwaiger M., Brunken R., Grover-McKay M., Krivokapich J., Child J., Tillisch J. H., Phelps M. E., Schelbert H. R. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol. 1986 Oct;8(4):800–808. doi: 10.1016/s0735-1097(86)80420-x. [DOI] [PubMed] [Google Scholar]
  22. Takeishi Y., Tono-oka I., Kubota I., Ikeda K., Masakane I., Chiba J., Abe S., Tsuiki K., Komatani A., Yamaguchi I. Functional recovery of hibernating myocardium after coronary bypass surgery: does it coincide with improvement in perfusion? Am Heart J. 1991 Sep;122(3 Pt 1):665–670. doi: 10.1016/0002-8703(91)90509-g. [DOI] [PubMed] [Google Scholar]
  23. Tillisch J., Brunken R., Marshall R., Schwaiger M., Mandelkern M., Phelps M., Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986 Apr 3;314(14):884–888. doi: 10.1056/NEJM198604033141405. [DOI] [PubMed] [Google Scholar]
  24. Topol E. J., O'Neill W. W., Langburd A. B., Walton J. A., Jr, Bourdillon P. D., Bates E. R., Grines C. L., Schork A. M., Kline E., Pitt B. A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction. Circulation. 1987 Feb;75(2):420–428. doi: 10.1161/01.cir.75.2.420. [DOI] [PubMed] [Google Scholar]
  25. Vanoverschelde J. L., Melin J. A., Bol A., Vanbutsele R., Cogneau M., Labar D., Robert A., Michel C., Wijns W. Regional oxidative metabolism in patients after recovery from reperfused anterior myocardial infarction. Relation to regional blood flow and glucose uptake. Circulation. 1992 Jan;85(1):9–21. doi: 10.1161/01.cir.85.1.9. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES